Question 1

Has Karen Klein received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $849,000 in general payments to Karen Klein across 416 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Karen Klein did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Karen Klein come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
AbbVie	160	$472,329
Ascendis Pharma Endocrinology Inc	80	$207,028
Tolmar, Inc.	22	$56,095
Eli Lilly	2	$55,250
Tolmar Pharmaceuticals, Inc.	24	$30,440
Ipsen Innovation	2	$12,198
Arbor Pharmaceuticals, Inc.	18	$7,794
Ipsen Biopharm Limited	1	$2,960
Ironwood Pharmaceuticals, Inc	2	$2,260
Novo Nordisk	30	$669
Ferring Pharmaceuticals Inc.	12	$306
Dexcom, Inc.	9	$255
BETA Bionics, Inc.	10	$248
Ipsen Biopharmaceuticals, Inc	8	$240
Azurity Pharmaceuticals, Inc.	10	$227
Eton Pharmaceuticals, Inc.	2	$123
Pfizer	5	$93
Neurocrine Biosciences, Inc.	3	$89
Kyowa Kirin, Inc.	3	$76
Insulet Corporation	2	$61
Medtronic	2	$56
Tandem Diabetes Care, Inc.	2	$49
Sandoz	2	$45
Sanofi-aventis U.S. LLC	2	$43
AstraZeneca	1	$24
Amgen	1	$23
Lilly USA, LLC	1	$19

Karen Klein

Payments from drug & device makers

Who reported the general payments

How this compares

Other pediatric endocrinology in San Diego